Sreenivasa R. Vanapalli

The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans

Monette Cotreau, Sarah Warren, John L. Ryan et al. · The Journal of Clinical Pharmacology · 2003 · 140 citations

Drug Safety, Antiparasitic Agent, Normal Cardiac +9

Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes

Leonid Katz, Jay J. Gambale, Paul Rothenberg et al. · Diabetes Obesity and Metabolism · 2012 · 107 citations

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of JNJ-38431055, a Novel GPR119 Receptor Agonist and Potential Antidiabetes Agent, in Healthy Male Subjects

Leonid Katz, Jay J. Gambale, Paul Rothenberg et al. · Clinical Pharmacology & Therapeutics · 2011 · 48 citations

Pharmacokinetics and dose proportionality of oral moxidectin in beagle dogs

Sreenivasa R. Vanapalli, Ya‐Ping Hung, Lawrence Fleckenstein et al. · Biopharmaceutics & Drug Disposition · 2002 · 43 citations

Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers

Sreenivasa R. Vanapalli, Y. Chen, V L Ellingrod et al. · Clinical Pharmacology & Therapeutics · 2003 · 21 citations

Molecular Pharmacology, Oral Bioavailability, Translational Pharmacology +10